Prenatal testing for hemolytic disease of the newborn and fetal neonatal alloimmune thrombocytopenia – current status

References

• Roopenian DC, Sun VZ. Clinical ramifications of the mhc family fc receptor fcrn. J Clin Immunol 2010;30:790-7
   PubMed Web of Science ®Google Scholar
• Urbaniak SJ. Consensus conference on anti-d prophylaxis. April 7 & 8, 1997: final consensus statement. Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynaecologists. Transfusion 1998;38(1):97-9
   PubMedGoogle Scholar
• Moise KJ. Hemolytic disease of the fetus and newborn. Clin Adv Hematol Oncol 2013;11:664-6
   PubMedGoogle Scholar
• Bennett PR, Le Van Kim C, Colin Y, et al. Prenatal determination of fetal rhd type by DNA amplification. N Engl J Med 1993;329:607-10
   PubMed Web of Science ®Google Scholar
• Lee S, Wu X, Reid M, et al. Molecular basis of the kell (k1) phenotype. Blood 1995;85:912-16
   PubMed Web of Science ®Google Scholar
• Avent ND, Martin PG. Kell typing by allele-specific pcr (asp). Br J Haematol 1996;93:728-30
   PubMedGoogle Scholar
• Olsson ML, Hansson C, Avent ND, et al. A clinically applicable method for determining the three major alleles at the duffy (fy) blood group locus using polymerase chain reaction with allele-specific primers. Transfusion 1998;38:168-73
   PubMedGoogle Scholar
• Le Van Kim C, Mouro I, Brossard Y, et al. Pcr-based determination of rhc and rhe status of fetuses at risk of rhc and rhe haemolytic disease. Br J Haematol 1994;88:193-5
   PubMedGoogle Scholar
• Avent ND. Antenatal genotyping of the blood groups of the fetus. Vox Sang 1998;74(Suppl 2):365-74
   PubMedGoogle Scholar
• Avent ND, Finning KM, Martin PG, Soothill PW. Prenatal determination of fetal blood group status. Vox Sang 2000;78(Suppl 2):155-62
   PubMedGoogle Scholar
• Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7
   PubMed Web of Science ®Google Scholar
• Faas BH, Beuling EA, Christiaens GC, et al. Detection of fetal rhd-specific sequences in maternal plasma. Lancet 1998;352:1196
   PubMed Web of Science ®Google Scholar
• Finning K, Martin P, Daniels G. A clinical service in the UK to predict fetal rh (rhesus) d blood group using free fetal DNA in maternal plasma. Ann N Y Acad Sci 2004;1022:119-23
   PubMed Web of Science ®Google Scholar
• Avent ND, Reid ME. The rh blood group system: a review. Blood 2000;95:375-87
   PubMed Web of Science ®Google Scholar
• Daniels G. Variants of rhd –current testing and clinical consequences. Br J Haematol 2013;161:461-70
   PubMed Web of Science ®Google Scholar
• Finning KM, Martin PG, Soothill PW, Avent ND. Prediction of fetal d status from maternal plasma: introduction of a new noninvasive fetal rhd genotyping service. Transfusion 2002;42:1079-85
   PubMed Web of Science ®Google Scholar
• Vogel T, Schmidtke J. Structure and function of tspy, the y-chromosome gene coding for the "testis-specific protein". Cytogenet Cell Genet 1998;80:209-13
   PubMedGoogle Scholar
• Avent ND, Chitty LS. Non-invasive diagnosis of fetal sex; utilisation of free fetal DNA in maternal plasma and ultrasound. Prenat Diagn 2006;26:598-603
   PubMedGoogle Scholar
• Scheffer PG, de Haas M, van der Schoot CE. The controversy about controls for fetal blood group genotyping by cell-free fetal DNA in maternal plasma. Curr Opin Hematol 2011;18:467-73
   PubMed Web of Science ®Google Scholar
• Chan KC, Ding C, Gerovassili A, et al. Hypermethylated rassf1a in maternal plasma: a universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 2006;52:2211-18
   PubMed Web of Science ®Google Scholar
• Kenny-Walsh E. Clinical outcomes after hepatitis c infection from contaminated anti-d immune globulin. Irish hepatology research group. N Engl J Med 1999;340:1228-33
   PubMed Web of Science ®Google Scholar
• Jakobsen TR, Clausen FB, Rode L, et al. High levels of fetal DNA are associated with increased risk of spontaneous preterm delivery. Prenat Diagn 2012;32:840-5
   PubMed Web of Science ®Google Scholar
• Jakobsen TR, Clausen FB, Rode L, et al. Identifying mild and severe preeclampsia in asymptomatic pregnant women by levels of cell-free fetal DNA. Transfusion 2013;53:1956-64
   PubMed Web of Science ®Google Scholar
• Haer-Wigman L, Veldhuisen B, Jonkers R, et al. Rhd and rhce variant and zygosity genotyping via multiplex ligation-dependent probe amplification. Transfusion 2013;53:1559-74
   PubMedGoogle Scholar
• Fan HC, Blumenfeld YJ, Chitkara U, et al. Analysis of the size distributions of fetal and maternal cell-free DNA by paired-end sequencing. Clin Chem 2010;56:1279-86
   PubMed Web of Science ®Google Scholar
• Yu SC, Chan KC, Zheng YW, et al. Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing. Proc Natl Acad Sci USA 2014;111:8583-8
   PubMed Web of Science ®Google Scholar
• Ghevaert C, Rankin A, Huiskes E, et al. Alloantibodies against low-frequency human platelet antigens do not account for a significant proportion of cases of fetomaternal alloimmune thrombocytopenia: evidence from 1054 cases. Transfusion 2009;49:2084-9
   PubMed Web of Science ®Google Scholar
• Koh Y, Ishii H, Amakishi E, et al. The first two cases of neonatal alloimmune thrombocytopenia associated with the low-frequency platelet antigen hpa-21bw (nos) in Japan. Transfusion 2012;52:1468-75
   PubMedGoogle Scholar
• Metcalfe P. Platelet antigens and antibody detection. Vox Sang 2004;87(Suppl1):82-6
   PubMedGoogle Scholar
• Bertrand G, Kaplan C. How do we treat fetal and neonatal alloimmune thrombocytopenia? Transfusion 2014;54(7):1698-703
   PubMedGoogle Scholar
• Gunnink SF, Vlug R, Fijnvandraat K, et al. Neonatal thrombocytopenia: etiology, management and outcome. Expert Rev Hematol 2014;7:387-95
   PubMed Web of Science ®Google Scholar
• Le Toriellec E, Chenet C, Kaplan C. Safe fetal platelet genotyping: new developments. Transfusion 2013;53:1755-62
   PubMedGoogle Scholar
• Scheffer PG, Ait Soussan A, Verhagen OJ, et al. Noninvasive fetal genotyping of human platelet antigen-1a. BJOG 2011;118:1392-5
   PubMed Web of Science ®Google Scholar
• Semple JW. Processed platelet hpa1a peptides au naturel. Blood 2009;114:1724-5
   PubMed Web of Science ®Google Scholar
• Kjeldsen-Kragh J, Ni H, Skogen B. Towards a prophylactic treatment of hpa-related foetal and neonatal alloimmune thrombocytopenia. Curr Opin Hematol 2012;19:469-74
   PubMedGoogle Scholar
• Ghevaert C, Herbert N, Hawkins L, et al. Recombinant hpa-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers. Blood 2013;122:313-20
   PubMedGoogle Scholar
• Szczepura A, Osipenko L, Freeman K. A new fetal rhd genotyping test: costs and benefits of mass testing to target antenatal anti-d prophylaxis in England and Wales. BMC Pregnancy Childbirth 2011;11:5
   PubMed Web of Science ®Google Scholar
• Avent ND. Large scale blood group genotyping. Transfus Clin Biol 2007;14:10-15
   PubMedGoogle Scholar
• Avent ND. Large-scale blood group genotyping: clinical implications. Br J Haematol 2009;144:3-13
   PubMed Web of Science ®Google Scholar
• Daniels G, van der Schoot CE, Olsson ML. Report of the fourth international workshop on molecular blood group genotyping. Vox Sang 2011;101:327-32
   PubMed Web of Science ®Google Scholar
• Veldhuisen B, van der Schoot CE, de Haas M. Blood group genotyping: from patient to high-throughput donor screening. Vox Sang 2009;97:198-206
   PubMedGoogle Scholar
• Westhoff CM. The potential of blood group genotyping for transfusion medicine practice. Immunohematol 2008;24:190-5
   PubMedGoogle Scholar
• Flegel WA. Blood group genotyping in Germany. Transfusion 2007;47:47S-53S
   Google Scholar
• Daniels G, Finning K, Martin P, Summers J. Fetal blood group genotyping: present and future. Ann N Y Acad Sci 2006;1075:88-95
   PubMedGoogle Scholar
• Agarwal A, Sayres LC, Cho MK, et al. Commercial landscape of noninvasive prenatal testing in the United States. Prenat Diagn 2013;33:521-31
   PubMed Web of Science ®Google Scholar